Topical Immunotherapy for Alopecia areata: Re-Evaluation of 139 Cases after an Additional Follow-Up Period of 19 Months

Steen, P.H.M. van der; Boezeman, J.B.M.; Happle, R

doi:10.1159/000247540

Cited by 53 publications

(35 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the investigated ‘prognostic factors’ for the outcome of DCP treatment, which have formerly been studied with variable results [14, 15, 16, 17, 18], we found only the type of AA to be of significance. In this context, it would be interesting to extend these studies to analyze possible correlations between genetic factors known to be associated with disease susceptibility and severity (certain HLA class II alleles, IL-1 and TNF-α gene polymorphisms [2, 4]) and the outcome of DCP treatment.…”

Section: Discussionmentioning

confidence: 88%

Topical Immunotherapy of Severe Alopecia areata with Diphenylcyclopropenone: Evaluation of 68 Cases

Pericin

Trüeb

1998

Dermatology

View full text Add to dashboard Cite

Background: Currently, topical immunotherapy with diphenylcyclopropenone (DCP) represents the most accepted therapeutic modality in the treatment of severe alopecia areata (AA). Objective: Efficacy, side effects and prognostic factors of DCP treatment in severe AA. Methods: Retrospective study of 68 patients with severe AA (>40% scalp hair loss), treated for at least 5 months at the Department of Dermatology, University Hospital of Zürich, between May 1989 and December 1996. Results: The overall response rate was 70.6%, complete remission was obtained in 30.9% and partial remission in 39.7%. Among the investigated prognostic factors for the outcome of DCP therapy, only the extent of AA at the time of initiation of treatment was found to be of significance. Conclusion: DCP treatment of severe AA is an effective, albeit symptomatic therapy with frequent side effects and a relatively high relapse rate. The response rate depends on the type of AA.

show abstract

Section: Discussionmentioning

confidence: 88%

Topical Immunotherapy of Severe Alopecia areata with Diphenylcyclopropenone: Evaluation of 68 Cases

Pericin

Trüeb

1998

Dermatology

View full text Add to dashboard Cite

show abstract

“…Except for contact immunotherapy [15,16], there are few data concerning the long-term benefits of therapies for AA. In their long-term follow-up study of 191 patients with mild-to-severe AA who were treated with various forms of therapy, Tosti et al [5] observed that 34.5% of patients were disease free after a follow-up period of 15–22 years (mean: 17.74 years), whereas 36.1% developed AT or AU.…”

Section: Discussionmentioning

confidence: 99%

Pulse Corticosteroid Therapy for Alopecia Areata: Long-Term Outcome after 10 Years

et al. 2012

View full text Add to dashboard Cite

Background: Few data are available concerning the efficiency of pulse corticosteroids in alopecia areata (AA). Objective: Our purpose was to assess the long-term outcomes of patients treated with methylprednisolone bolus. Methods: This study included 60 patients treated between 1995 and 2000. The short-term outcomes were analyzed in 2000. The long-term assessment of 30 patients was performed in 2010 by phone questionnaire. Results: Significant hair regrowth was observed in 10/30 patients at 6 months after the bolus treatment. Half of the plurifocalis AA patients were responders at 6 months, but less than one quarter of alopecia totalis (AT) and alopecia universalis (AU) patients responded. Long-term outcomes were assessed after a mean duration of 12.3 years; 8/10 initial responders had mild or no disease, and 14/20 initial nonresponders had severe AA. Conclusions: This study confirmed the low efficiency, both short- and long-term, of this treatment for AT and AU.

show abstract

“…To date, topical immunotherapy in clinically controlled studies has been shown to be the most effective method of available treatment [11,12]. Topical immunotherapy involves intermittently inducing allergic contact dermatitis on the scalp [12,13].…”

Section: Discussionmentioning

confidence: 99%

“…Topical immunotherapy involves intermittently inducing allergic contact dermatitis on the scalp [12,13]. Two studies examined the efficacy and tolerability of diphenylcyclopropenone in the treatment of severe alopecia areata.…”

Section: Discussionmentioning

confidence: 99%

Treatment of alopecia areata with the 308‐nm xenon chloride excimer laser: Case report of two successful treatments with the excimer laser

2004

View full text Add to dashboard Cite

The use of the excimer laser is an effective, elegant, and safe means of treatment and has good tolerability. Analogous to topical treatment of alopecia areata, the immunosuppressive mechanism of the excimer laser can be interpreted as an induction of T-cell apoptosis. This new means of treatment has yet to be discussed in medical literature. Further studies with greater numbers are needed to assess its potential more precisely and evaluate the excimer laser in treating alopecia areata.

show abstract

Topical Immunotherapy for Alopecia areata: Re-Evaluation of 139 Cases after an Additional Follow-Up Period of 19 Months

Cited by 53 publications

References 4 publications

Topical Immunotherapy of Severe Alopecia areata with Diphenylcyclopropenone: Evaluation of 68 Cases

Topical Immunotherapy of Severe Alopecia areata with Diphenylcyclopropenone: Evaluation of 68 Cases

Pulse Corticosteroid Therapy for Alopecia Areata: Long-Term Outcome after 10 Years

Treatment of alopecia areata with the 308‐nm xenon chloride excimer laser: Case report of two successful treatments with the excimer laser

Contact Info

Product

Resources

About